Feedback

Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis

Affiliation
Chengdu Second People’s Hospital ,Chengdu ,Sichuan ,China
Tong, Yitong;
Affiliation
Department of Pharmacy ,Personalized Drug Therapy Key Laboratory of Sichuan Province ,Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Chengdu ,Sichuan ,China
Li, Xinyu;
Affiliation
Department of Pharmacy ,Personalized Drug Therapy Key Laboratory of Sichuan Province ,Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Chengdu ,Sichuan ,China
Deng, Qichuan;
Affiliation
Department of Pharmacy ,Personalized Drug Therapy Key Laboratory of Sichuan Province ,Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Chengdu ,Sichuan ,China
Shi, Jianyou;
Affiliation
School of Chinese Medicine ,The University of Hong Kong ,Shatin ,Hong Kong SAR, China
Feng, Yibin;
Affiliation
Department of Pharmacy ,Personalized Drug Therapy Key Laboratory of Sichuan Province ,Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Chengdu ,Sichuan ,China
Bai, Lan

Rheumatoid arthritis (RA) is a type of chronic autoimmune and inflammatory disease. In the pathological process of RA, the alteration of fibroblast-like synoviocyte (FLS) and its related factors is the main influence in the clinic and fundamental research. In RA, FLS exhibits a uniquely aggressive phenotype, leading to synovial hyperplasia, destruction of the cartilage and bone, and a pro-inflammatory environment in the synovial tissue for perpetuation and progression. Evidently, it is a highly promising way to target the pathological function of FLS for new anti-RA drugs. Based on this, we summed up the pathological mechanism of RA-FLS and reviewed the recent progress of small molecule drugs, including the synthetic small molecule compounds and natural products targeting RA-FLS. In the end, there were some views for further action. Compared with MAPK and NF-κB signaling pathways, the JAK/STAT signaling pathway has great potential for research as targets. A small number of synthetic small molecule compounds have entered the clinic to treat RA and are often used in combination with other drugs. Meanwhile, most natural products are currently in the experimental stage, not the clinical trial stage, such as triptolide. There is an urgent need to unremittingly develop new agents for RA.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Tong, Li, Deng, Shi, Feng and Bai.

Use and reproduction: